EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSPVAG00000014824
Gene Symbol: SIGMAR1
1 Cross references
204 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSPVAG00000007129
Gene Symbol: SIRT1
1 Cross references
157 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSPVAG00000003377
Gene Symbol: SMO
1 Cross references
204 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSPVAG00000012558
Gene Symbol: SCNN1A
1 Cross references
153 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSPVAG00000002693
Gene Symbol: SCNN1B
1 Cross references
151 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSPVAG00000011219
Gene Symbol: SCNN1G
1 Cross references
155 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSPVAG00000017941
Gene Symbol: SCN1A
1 Cross references
139 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSPVAG00000006921
Gene Symbol: SCN10A
1 Cross references
297 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSPVAG00000006923
Gene Symbol: SCN11A
1 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSPVAG00000015231
Gene Symbol: SCN2A
1 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSPVAG00000015226
Gene Symbol: SCN3A
1 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSPVAG00000000481
Gene Symbol: SCN4A
1 Cross references
193 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).